Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Nov 09, 2023 $28.50 $28.63 $24.72 $24.96 2 938 852
Nov 08, 2023 $29.49 $29.66 $28.12 $28.45 1 296 533
Nov 07, 2023 $27.82 $29.60 $27.42 $29.49 1 447 990
Nov 06, 2023 $28.60 $28.71 $27.08 $27.66 1 457 767
Nov 03, 2023 $27.11 $29.02 $27.06 $28.76 2 367 713
Nov 02, 2023 $26.10 $26.53 $25.57 $26.48 1 585 206
Nov 01, 2023 $25.25 $25.56 $24.38 $25.50 1 629 730
Oct 31, 2023 $23.90 $25.16 $23.67 $25.05 1 134 610
Oct 30, 2023 $23.42 $24.45 $22.81 $23.83 1 774 221
Oct 27, 2023 $25.45 $25.45 $23.01 $23.16 1 867 637
Oct 26, 2023 $24.70 $25.83 $24.46 $25.00 2 142 618
Oct 25, 2023 $26.12 $26.27 $24.24 $24.38 1 489 685
Oct 24, 2023 $26.64 $27.62 $26.48 $26.64 1 192 909
Oct 23, 2023 $26.32 $26.93 $25.84 $26.32 1 071 994
Oct 20, 2023 $27.06 $27.50 $26.52 $26.64 1 160 656
Oct 19, 2023 $28.00 $28.15 $26.65 $27.10 1 730 149
Oct 18, 2023 $29.51 $29.64 $27.35 $27.96 1 967 536
Oct 17, 2023 $29.33 $29.84 $28.99 $29.05 913 024
Oct 16, 2023 $29.82 $30.28 $29.24 $29.63 668 170
Oct 13, 2023 $29.01 $30.00 $28.81 $29.83 623 982
Oct 12, 2023 $30.29 $30.39 $28.73 $28.91 979 394
Oct 11, 2023 $30.14 $30.74 $29.78 $30.25 702 677
Oct 10, 2023 $30.02 $30.86 $29.96 $30.13 756 077
Oct 09, 2023 $29.46 $30.14 $28.95 $30.03 793 859
Oct 06, 2023 $30.11 $30.64 $29.81 $30.04 759 554
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT